<?xml version='1.0' encoding='utf-8'?>
<document id="24464803"><sentence text="The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans."><entity charOffset="62-73" id="DDI-PubMed.24464803.s1.e0" text="tofacitinib" /></sentence><sentence text="Tofacitinib is a novel, oral Janus kinase inhibitor"><entity charOffset="0-11" id="DDI-PubMed.24464803.s2.e0" text="Tofacitinib" /></sentence><sentence text=" The objectives of this study were to summarize the pharmacokinetics and metabolism of tofacitinib in humans, including clearance mechanisms"><entity charOffset="87-98" id="DDI-PubMed.24464803.s3.e0" text="tofacitinib" /></sentence><sentence text=" Following administration of a single 50-mg (14)C-labeled tofacitinib dose to healthy male subjects, the mean (standard deviation) total percentage of administered radioactive dose recovered was 93" /><sentence text="9% (±3" /><sentence text="6), with 80" /><sentence text="1% (±3" /><sentence text="6) in the urine (28" /><sentence text="8% parent), and 13" /><sentence text="8% (±1" /><sentence text="9) in feces (0" /><sentence text="9% parent)" /><sentence text=" Tofacitinib was rapidly absorbed, with plasma concentrations and total radioactivity peaking at around 1 hour after oral administration"><entity charOffset="1-12" id="DDI-PubMed.24464803.s13.e0" text="Tofacitinib" /></sentence><sentence text=" The mean terminal phase half-life was approximately 3" /><sentence text="2 hours for both parent drug and total radioactivity" /><sentence text=" Most (69" /><sentence text="4%) circulating radioactivity in plasma was parent drug, with all metabolites representing less than 10% each of total circulating radioactivity" /><sentence text=" Hepatic clearance made up around 70% of total clearance, while renal clearance made up the remaining 30%" /><sentence text=" The predominant metabolic pathways of tofacitinib included oxidation of the pyrrolopyrimidine and piperidine rings, oxidation of the piperidine ring side-chain, N-demethylation and glucuronidation"><entity charOffset="39-50" id="DDI-PubMed.24464803.s19.e0" text="tofacitinib" /><entity charOffset="77-94" id="DDI-PubMed.24464803.s19.e1" text="pyrrolopyrimidine" /><entity charOffset="99-109" id="DDI-PubMed.24464803.s19.e2" text="piperidine" /><entity charOffset="134-144" id="DDI-PubMed.24464803.s19.e3" text="piperidine" /><pair ddi="false" e1="DDI-PubMed.24464803.s19.e0" e2="DDI-PubMed.24464803.s19.e0" /><pair ddi="false" e1="DDI-PubMed.24464803.s19.e0" e2="DDI-PubMed.24464803.s19.e1" /><pair ddi="false" e1="DDI-PubMed.24464803.s19.e0" e2="DDI-PubMed.24464803.s19.e2" /><pair ddi="false" e1="DDI-PubMed.24464803.s19.e0" e2="DDI-PubMed.24464803.s19.e3" /><pair ddi="false" e1="DDI-PubMed.24464803.s19.e1" e2="DDI-PubMed.24464803.s19.e1" /><pair ddi="false" e1="DDI-PubMed.24464803.s19.e1" e2="DDI-PubMed.24464803.s19.e2" /><pair ddi="false" e1="DDI-PubMed.24464803.s19.e1" e2="DDI-PubMed.24464803.s19.e3" /><pair ddi="false" e1="DDI-PubMed.24464803.s19.e2" e2="DDI-PubMed.24464803.s19.e2" /><pair ddi="false" e1="DDI-PubMed.24464803.s19.e2" e2="DDI-PubMed.24464803.s19.e3" /></sentence><sentence text=" Cytochrome P450 (P450) profiling indicated that tofacitinib was mainly metabolized by CYP3A4, with a smaller contribution from CYP2C19"><entity charOffset="49-60" id="DDI-PubMed.24464803.s20.e0" text="tofacitinib" /></sentence><sentence text=" This pharmacokinetic characterization of tofacitinib has been consistent with its clinical experience in drug-drug interaction studies"><entity charOffset="42-53" id="DDI-PubMed.24464803.s21.e0" text="tofacitinib" /></sentence><sentence text=" " /></document>